Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated traditional Chinese medicine versus TACE-based management for primary liver cancer
ChiCTR-TRC-07000033Phase 4Completed
- Sponsor
- Changhai Hospital
- Start
- Oct 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cinobufotalin, brentuximab vedotin, huaier granule, epirubicin, fluorouracil and 2 more in hepatocellular carcinoma (HCC) (4 arms), sponsored by Changhai Hospital. Primary endpoints: Time to progression, Relapse rate and 3 more. Started Oct 2006; status: completed.
02
Drugs
cinobufotalinbrentuximab vedotinhuaier granuleepirubicinfluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-07000033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-07000033.